FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Ophthalmol / Corneal and scleral permeability of Desmoteplase in differen...
Veterinary ophthalmology2020; 23(5); 785-791; doi: 10.1111/vop.12782

Corneal and scleral permeability of Desmoteplase in different species.

Abstract: Intraocular fibrin clots caused by severe uveitis can be a sight-threatening condition that needs to be resolved quickly and reliably. Intracameral injection of tissue-plasminogen activator (tPA) is commonly used to resolve intraocular fibrin. However, the drug does not reach fibrinolytic concentrations after topical application. Desmoteplase (DSPA) is a structurally similar but smaller fibrinolytic agent with a higher fibrin selectivity, a longer half-life, and better biocompatibility compared with tPA. This study was designed to evaluate the corneal and scleral permeability of DSPA in rabbits, pigs, dogs, horses, and humans ex vivo. Methods: Corneal and scleral tissues (n = 5 per group) were inserted into Franz-type diffusion chambers and exposed to 1.4 mg/mL DSPA for 30 minutes. Drug concentrations on the receiver side were determined by liquid chromatography-tandem mass spectrometry. Results: Concentrations of DSPA after corneal and scleral permeation through fresh tissues ranged from 0.0 to 16.3 µg/mL and 0.0 to 11.4 µg/mL (rabbits), 0.3 to 5.6 µg/mL and 3.1 to 9.2 µg/mL (dogs), 2.1 to 14.9 µg/mL and 4 to 8.7 µg/mL (horses), and 0.6 to 3 µg/mL and 2.9 to 18.1 µg/mL (pigs), respectively. A concentration of 0.07-12.9 µg/mL DSPA was detectable after diffusion through tissue culture preserved human donor bank corneas (Table 1). Conclusions: Desmoteplase has the ability to permeate both cornea and sclera ex vivo in all species tested. Implications of the ex vivo permeability of DSPA suggest that in vivo permeability may be possible, and if so, it could lead to a novel topical application for lysing fibrin.
© 2020 American College of Veterinary Ophthalmologists.
Get Full Text
Publication Date: 2020-08-30 PubMed ID: 32862517DOI: 10.1111/vop.12782Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study discovered that Desmoteplase, a fibrinolytic agent, has the capacity to penetrate both the cornea and sclera in various animal species as well as in human tissue, which might result in a novel way of applying the drug to treat visual threatening conditions caused by intraocular fibrin clots.

Introduction

  • The research is centered on the treatment of intraocular fibrin clots that may cause sight-threatening situations in conditions like severe uveitis.
  • Traditionally, the commonly used means of resolving these fibrin clots is through an intraocular injection of tissue-plasminogen activator (tPA). This method has its limitations, though, as the drug does not reach fibrinolytic concentrations after topical application.
  • The study proposes the use of Desmoteplase (DSPA), a smaller fibrinolytic agent which has a higher fibrin selectivity, a longer half-life and better biocompatibility compared to tPA.

Methods

  • Different species including rabbits, pigs, dogs, horses, and humans were subjected to the study.
  • The researchers evaluated the permeability of DSPA in the corneal and scleral tissues of these species through an ex vivo experiment.
  • They inserted corneal and scleral tissues into Franz-type diffusion chambers and exposed the tissues to 1.4 mg/mL DSPA solution for 30 minutes.
  • They used liquid chromatography-tandem mass spectrometry to determine drug concentration on the receiver side.

Results

  • The results showed DSPA concentrations after corneal and scleral permeation through the fresh tissues of rabbits, dogs, horses and pigs fell within definite ranges, showing that DSPA was able to penetrate the tissues.
  • When using tissue culture preserved human donor bank corneas, DSPA was detectable after diffusion.

Conclusion

  • Based on these results, it was concluded that DSPA has the ability to permeate both the cornea and sclera of all species tested in the study.
  • These findings suggest the possibility of in vivo permeability, which indicates that DSPA could potentially be used in a novel way for the topical treatment for lysing fibrin, an application that could aid in the treatment of sight-threatening conditions.

Cite This Article

APA
Brütsch DR, Hunziker P, Pot S, Tappeiner C, Voelter K. (2020). Corneal and scleral permeability of Desmoteplase in different species. Vet Ophthalmol, 23(5), 785-791. https://doi.org/10.1111/vop.12782

Publication

Veterinary ophthalmology
ISSN: 1463-5224
NlmUniqueID: 100887377
Country: England
Language: English
Volume: 23
Issue: 5
Pages: 785-791

Researcher Affiliations

Brütsch, Deborah R
  • Ophthalmology Section, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Hunziker, Peter
  • Functional Genomics Center Zurich, University of Zurich, Zurich, Switzerland.
Pot, Simon
  • Ophthalmology Section, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Tappeiner, Christoph
  • Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Voelter, Katrin
  • Ophthalmology Section, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

MeSH Terms

  • Animals
  • Cornea / drug effects
  • Cornea / metabolism
  • Dogs
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / pharmacology
  • Horses
  • Humans
  • Ophthalmic Solutions
  • Permeability
  • Plasminogen Activators / administration & dosage
  • Plasminogen Activators / pharmacology
  • Rabbits
  • Sclera / drug effects
  • Sclera / metabolism
  • Species Specificity
  • Swine
  • Uveitis / drug therapy
  • Uveitis / veterinary

Grant Funding

  • ECVO

References

This article includes 48 references
  1. Gelatt KN, Gilger BC, Kern TJ. Chapter 20 - Diseases and surgery of the canine anterior uvea.. 2013.
  2. Yanoff M, Sassani JW. Ocular Pathology.. 2009.
  3. Baruah DB, Dash RN, Chaudhari MR, Kadam SS. Plasminogen activators: a comparison.. Vascul Pharmacol 2006;44(1):1-9.
  4. Gerding PA Jr, Essex-Sorlie D, Vasaune S, Yack R. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.. Am J Vet Res 1992;53(6):894-896.
  5. Gerding PA Jr, Hamor RE, Ramsey DT, Vasaune S, Schaeffer DJ. Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.. Am J Vet Res 1994;55(10):1368-1370.
  6. Tripathi RC, Tripathi BJ. Tissue plasminogen activator therapy for the eye.. Br J Ophthalmol 2005;89(11):1390-1391.
  7. Kumar A, Pulicherla K, Seetha Ram K, Rao KS. Evolutionary trend of thrombolytics.. Int J Bio-Sci Bio-Technol 2010;2(4):51-68.
  8. Zalta AH, Sweeney CP, Zalta AK, Kaufman AH. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants.. Arch Ophthalmol 2002;120(11):1487-1493.
  9. Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P Jr, Meredith TA, Ward AR. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.. Am J Ophthalmol 1990;110(4):354-360.
  10. Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review.. Ophthalmology 2003;110(4):704-708.
  11. Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.. Arch Ophthalmol 2000;118(5):659-663.
  12. Yoeruek E, Spitzer MS, Tatar O. Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells.. Invest Ophthalmol Vis Sci 2008;49(4):1392-1397.
  13. Gerding PA Jr, Essex-Sorlie D, Yack R, Vasaune S. Effects of intracameral injection of tissue plasminogen activator on corneal endothelium and intraocular pressure in dogs.. Am J Vet Res 1992;53(6):890-893.
  14. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke.. Br J Pharmacol 2012;165(1):75-89.
  15. Gardell SJ, Duong LT, Diehl RE. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.. J Biol Chem 1989;264(30):17947-17952.
  16. Gardell SJ, Ramjit DR, Stabilito II. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.. Circulation 1991;84(1):244-253.
  17. Mellott MJ, Stabilito II, Holahan MA. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.. Arterioscler Thromb 1992;12(2):212-221.
  18. Freeman R, Niego B, Croucher DR, Pedersen LO, Medcalf RL. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.. Brain Res 2014;1565:63-73.
  19. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.. Stroke 2003;34(2):537-543.
  20. Reddrop C, Moldrich RX, Beart PM. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.. Stroke 2005;36(6):1241-1246.
  21. Voelter K, Tappeiner C, Klein K. Fibrinolytic capacity of desmoteplase compared to tissue plasminogen activator in rabbit eyes.. J Ocul Pharmacol Ther 2019;35(1):66-75.
  22. Gelatt KN, Gilger BC, Kern TJ. Chapter 7 - Clinical pharmacology and therapeutics.. 2013.
  23. Ghate D, Edelhauser HF. Ocular drug delivery.. Expert Opin Drug Deliv 2006;3(2):275-287.
  24. Pescina S, Govoni P, Antopolsky M. Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update.. J Pharm Sci 2015;104(7):2190-2202.
  25. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera.. Invest Ophthalmol Vis Sci 1997;38(3):627-634.
  26. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery.. AAPS J 2010;12(3):348-360.
  27. Ambati J, Canakis CS, Miller JW. Diffusion of high molecular weight compounds through sclera.. Invest Ophthalmol Vis Sci 2000;41(5):1181-1185.
  28. Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness.. Vet Ophthalmol 2005;8(4):265-269.
  29. Doane MG, Jensen AD, Dohlman CH. Penetration routes of topically applied eye medications.. Am J Ophthalmol 1978;85(3):383-386.
  30. Miao H, Wu BD, Tao Y, Li XX. Diffusion of macromolecules through sclera.. Acta Ophthalmol 2013;91(1):e1-6.
  31. Lim JI, Fiscella R, Tessler H, Gagliano DA, Chaques-Alepuz V, Mohler MA. Intraocular penetration of topical tissue plasminogen activator.. Arch Ophthalmol 1991;109(5):714-717.
  32. Majumdar S, Hingorani T, Srirangam R. Evaluation of active and passive transport processes in corneas extracted from preserved rabbit eyes.. J Pharm Sci 2010;99(4):1921-1930.
  33. Smith VA, Johnson T. Evaluation of Megacell MEM as a storage medium for corneas destined for transplantation.. Ophthalmic Res 2010;43(1):18-25.
  34. Hacke W, Albers G, Al-Rawi Y. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.. Stroke 2005;36(1):66-73.
  35. Pescina S, Govoni P, Potenza A, Padula C, Santi P, Nicoli S. Development of a convenient ex vivo model for the study of the transcorneal permeation of drugs: histological and permeability evaluation.. J Pharm Sci 2015;104(1):63-71.
  36. MacLean B, Tomazela DM, Shulman N. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.. Bioinformatics 2010;26(7):966-968.
  37. Abbatiello SE, Mani DR, Schilling B. Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS).. Mol Cell Proteomics 2013;12(9):2623-2639.
  38. Wang X, Wu Q. Normal corneal thickness measurements in pigmented rabbits using spectral-domain anterior segment optical coherence tomography.. Vet Ophthalmol 2013;16(2):130-134.
  39. Liu TX, Wang Z. Biomechanics of sclera crosslinked using genipin in rabbit.. Int J Ophthalmol 2017;10(3):355-360.
  40. Hoehn AL, Thomasy SM, Kass PH. Comparison of ultrasonic pachymetry and Fourier-domain optical coherence tomography for measurement of corneal thickness in dogs with and without corneal disease.. Vet J 2018;242:59-66.
  41. Pirie CG, Alario AF, Barysauskas CM, Gradil C, Uricchio CK. Manual corneal thickness measurements of healthy equine eyes using a portable spectral-domain optical coherence tomography device.. Equine Vet J 2014;46(5):631-634.
  42. Realini T, Gurka MJ, Weinreb RN. Reproducibility of central corneal thickness measurements in healthy and glaucomatous eyes.. J Glaucoma 2017;26(9):787-791.
  43. Norman RE, Flanagan JG, Rausch SM. Dimensions of the human sclera: thickness measurement and regional changes with axial length.. Exp Eye Res 2010;90(2):277-284.
  44. Loch C, Zakelj S, Kristl A. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes.. Eur J Pharm Sci 2012;47(1):131-138.
  45. Agarwal P, Rupenthal ID. In vitro and ex vivo corneal penetration and absorption models.. Drug Deliv Transl Res 2016;6(6):634-647.
  46. Maggs DM, Miller PE, Ofri R, Slatter DH. Sletter's Fundamentals of Veterinary Ophthalmology.. 2013.
  47. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery.. Drug Dev Ind Pharm 2013;39(11):1599-1617.
  48. The 3Rs: National Centre for the Replacement Refinement & Reduction of Animals in Research; Available from: https://www.nc3rs.org.uk/the-3rs. Accessed November 19, 2019.

Citations

This article has been cited 1 times.
  1. Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.. Eur J Drug Metab Pharmacokinet 2022 Mar;47(2):165-176.
    doi: 10.1007/s13318-021-00743-8pubmed: 34893967google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.